Trial Profile
Intranasal Bevacizumab for HHT-Related Epistaxis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Sep 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Epistaxis
- Focus Therapeutic Use
- 29 Aug 2020 Status changed from recruiting to completed.
- 19 Dec 2018 Planned End Date changed from 1 Mar 2019 to 1 Dec 2019.
- 19 Dec 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Sep 2019.